Advanced Illness and Post-Acute Care
This project includes measures of advanced illness and/or end-stage disease management, palliative and hospice care, post-acute care and home care.
Advanced Illness and Post-Acute Care
With its focus on improving quality of life, advanced illness and/or post-acute care are distinct from care intended to cure an illness or condition, although it can be delivered concurrently with curative therapies. Advanced illness care focuses on medical care for people living with a serious illness. It aims to address the symptoms or stress related to the illness and improve the overall experience and/or quality of life for patients, caregivers, and family members. Advanced illness care may also include palliative and hospice care, which includes comprehensive care that addresses medical, emotional, spiritual, and social needs during the last stages of a person’s terminal illness.
Post-acute care includes medical or supportive care provided to individuals after leaving an acute care setting, such as a hospital, but they are not ready to return home. This includes rehabilitation and even palliative care services.
The Advanced Illness and Post-Acute Care committee considers measures that address post-acute care and advanced illness, including cancer and end-stage disease (e.g., end-stage renal disease). Subtopics may include advanced illness management, the assessment of physical, emotional, social, psychological, and spiritual aspects of care, access to and timeliness of care, patient and family experience with care, patient and family engagement, care planning, hospice care, palliative and end-of-life care, chemotherapy, rescue, and intensive care unit (ICU) care.
Valid for Measure Submission
✔
Advanced Illness and Post-Acute Care Advisory Group Meeting
The purpose of this meeting is for Advisory Group members to raise questions and share perspectives verbally regarding the measures under endorsement review for their respective E&M committee. No voting occurs during these virtual meetings. Rather, Advisory Group members will be asked to review the measures assigned to their respective committee and come to the meeting to ask questions and provide feedback regarding the strengths and limitations of the measures.
Advanced Illness and Post-Acute Care Advisory Group Meeting
The purpose of this meeting is for Advisory Group members to raise questions and share perspectives verbally regarding the measures under endorsement review for their respective E&M committee. No voting occurs during these virtual meetings. Rather, Advisory Group members will be asked to review the measures assigned to their respective committee and come to the meeting to ask questions and provide feedback regarding the strengths and limitations of the measures.
Advanced Illness and Post-Acute Care Advisory Group Meeting
The purpose of this meeting is for Advisory Group members to raise questions and share perspectives verbally regarding the measures under endorsement review for their respective E&M committee. No voting occurs during these virtual meetings. Rather, Advisory Group members will be asked to review the measures assigned to their respective committee and come to the meeting to ask questions and provide feedback regarding the strengths and limitations of the measures.
Advanced Illness and Post-Acute Care Advisory Group Meeting
The purpose of this meeting is for Advisory Group members to raise questions and share perspectives verbally regarding the measures under endorsement review for their respective E&M committee. No voting occurs during these virtual meetings. Rather, Advisory Group members will be asked to review the measures assigned to their respective committee and come to the meeting to ask questions and provide feedback regarding the strengths and limitations of the measures.
Advanced Illness and Post-Acute Care Endorsement Meeting
The purpose of this meeting is for Recommendation Group members to discuss and share perspectives regarding the measures under endorsement review for their respective E&M committee. Endorsement voting occurs during these virtual meetings. Advisory Group members are invited to attend these Recommendation Group meetings to listen to the discussion. Measure developers/stewards are invited and encouraged to attend, as they will have the opportunity to respond to the Recommendation Group discussion during the meeting.
Advanced Illness and Post-Acute Care Endorsement Meeting
The purpose of this meeting is for Recommendation Group members to discuss and share perspectives regarding the measures under endorsement review for their respective E&M committee. Endorsement voting occurs during these virtual meetings. Advisory Group members are invited to attend these Recommendation Group meetings to listen to the discussion. Measure developers/stewards are invited and encouraged to attend, as they will have the opportunity to respond to the Recommendation Group discussion during the meeting.
Advanced Illness and Post-Acute Care Recommendation Group Meeting
The purpose of this meeting is for Recommendation Group members to discuss and share perspectives regarding the measures under endorsement review for their respective E&M committee. Endorsement voting occurs during these virtual meetings. Advisory Group members are invited to attend these Recommendation Group meetings to listen to the discussion. Measure developers/stewards are invited and encouraged to attend, as they will have the opportunity to respond to the Recommendation Group discussion during the meeting.
Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy
Description
Percentage of patients aged 18 years and older with a diagnosis of chronic kidney disease (CKD) (Stages 1-5, not receiving Renal Replacement Therapy (RRT)) and proteinuria who were prescribed ACE inhibitor or ARB therapy within a 12-month period.
This measure is NQF Measure 1662/MIPS Measure 489.
CBE ID
1662
Bereaved Family Survey - Performance Measure (BFS-PM) Score (%) for all Veteran Affairs Medical Center Inpatient Deaths
Description
The Bereaved Family Survey-Performance Measure (BFS-PM) is an outcome measure that is used to assess overall quality of care in the last month of life. Currently, the BFS is administered to the next-of-kin of all Veterans who die in a VA inpatient setting (i.e., acute units, intensive care units, inpatient hospice and palliative care units, and VA nursing homes) 4-6 weeks post-death. The BFS-PM is calculated using the global rating item included on the 20-item BFS that has separate versions for male and female Veterans and is available in English and Spanish.
CBE ID
1623